Social reactions to Valium and Prozac: a cultural lag perspective of drug diffusion and adoption.
BACKGROUND
In the sociological context, the concept of cultural lag holds that material technologies advance more rapidly than social guidelines for their use. The result can be social conflict including liability accusations and product stigmatization that have characterized several new drugs which were widely accepted initially but then publicly criticized in the lay and scientific press.


OBJECTIVE
The objective was to illustrate the utility of the concept of cultural lag to technology commercialization by applying cultural lag to the social and professional environments surrounding the diffusion of the "minor tranquilizers" Librium and Valium in the United States from the 1950s to the 1970s, and the antidepressant Prozac from 1987 to 2005. The intention is to develop a perspective from which to view patterns of social acceptance followed by critique that may occur when technological advances are introduced to the marketplace.


METHODS
This study systematically reviews academic, medical, and lay literature regarding the diffusion of the "minor tranquilizers" Librium and Valium in the United States from the 1950s to the 1970s, and the antidepressant Prozac from 1987 to 2005.


RESULTS
The minor tranquilizers and Prozac both reveal similar patterns of initial widespread public endorsement, followed by growing public criticism and recommendations for more restrictive usage guidelines.


CONCLUSIONS
Cultural lag provides a perspective from which to anticipate, view, and avoid controversies that develop from new technologies in general and pharmaceutical technologies in particular. Market demands for rapid introduction must be balanced by public education. This requires proactive encouragement of lay and professional discussions and the establishment of marketing guidelines that aid development of social consensus regarding appropriate usage.
Marshall
Kimball P
KP
Alcorn State University, School of Business - MBA Program, 9 Campus Drive, Natchez, MS 39122, USA. kimball.p.marshall@netzero.net
Georgievskava
Zhanna
Z
Georgievsky
Igor
I
D014151:Anti-Anxiety Agents / Q000266:history / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000266:history / Q000627:therapeutic use; D002707:Chlordiazepoxide / Q000266:history / Q000627:therapeutic use; D003469:Culture; D003975:Diazepam / Q000266:history / Q000627:therapeutic use*; D004345:Drug Industry / Q000379:methods; D005473:Fluoxetine / Q000266:history / Q000627:therapeutic use*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D040541:Marketing / Q000379:methods; D011639:Public Opinion; D012931:Social Environment
D014151:Anti-Anxiety Agents; D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D002707:Chlordiazepoxide; D003975:Diazepam